文献速递胸部肿瘤支持与姑息治疗

合并症负担:非小细胞肺癌随访期间的骨质疏松性椎体骨折——BONE研究

Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study.
PubMed 文献 · Eur J Cancer · 2024-02-05

该单中心回顾性队列研究纳入289例组织学确诊的任何分期非小细胞肺癌患者,通过双盲复核胸腹盆CT评估骨质疏松性椎体骨折(OPVF)的患病率、发病率、危险因素及对总生存的影响。随访中位29.7个月,OPVF患病率从基线10.7%升至随访结束23.2%,累积发病率12.5%,发病密度4例/100患者年;BMI<19 kg/m²、较低骨小梁体积骨密度和糖皮质激素使用为独立危险因素;OPVF与总生存无显著关联。

要点

  • 非小细胞肺癌患者随访期间OPVF累积发病率为12.5%,发病密度4例/100患者年。
  • BMI<19 kg/m²、较低骨小梁体积骨密度及糖皮质激素使用为OPVF独立危险因素。
  • OPVF与总生存无显著关联。

核心结论

  • 非小细胞肺癌患者应筛查骨质疏松,胸部肿瘤科医生须扩大糖皮质激素诱导骨质疏松推荐的使用范围。

研究设计与样本

  • 纵向单中心回顾性队列研究,纳入289例组织学确诊的任何分期非小细胞肺癌患者。

主要发现

  • OPVF患病率基线为10.7%,随访结束时为23.2%;累积发病率为12.5%,发病密度为4例/100患者年。
  • 发生OPVF的中位时间为13个月(IQR:6.7-21.2)。
  • 36例发生OPVF的患者中7例接受了地舒单抗或双膦酸盐治疗。
  • 多因素分析中,发生OPVF的独立危险因素包括BMI<19 kg/m²(OR:5.62,95%CI 1.84-17.20,p=0.002)、较低骨小梁体积骨密度(每HU OR:0.982,95%CI 0.97-0.99,p=0.001)和糖皮质激素使用(OR:4.77,95%CI:1.76-12.89,p=0.001)。
  • OPVF与总生存无显著关联。

关键数值与推荐

  • OPVF患病率基线10.7%,随访结束时23.2%;累积发病率12.5%,发病密度4例/100患者年。
  • 发生OPVF的中位时间13个月(IQR:6.7-21.2)。
  • BMI<19 kg/m²的OPVF发生OR为5.62(95%CI 1.84-17.20,p=0.002)。
  • 骨小梁体积骨密度每HU的OPVF发生OR为0.982(95%CI 0.97-0.99,p=0.001)。
  • 糖皮质激素使用的OPVF发生OR为4.77(95%CI:1.76-12.89,p=0.001)。

临床怎么用

  • 作者认为非小细胞肺癌患者应筛查骨质疏松。
  • 作者认为胸部肿瘤科医生必须扩大糖皮质激素诱导骨质疏松推荐的使用范围。
  • 36例发生OPVF的患者中7例接受了地舒单抗或双膦酸盐治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immunotherapy and targeted therapy have extended life expectancy in non-small cell lung cancer (NSCLC) patients, shifting it into a chronic condition with comorbidities, including osteoporosis. This study aims to evaluate the prevalence and incidence of osteoporotic vertebral fracture (OPVF) during NSCLC follow-up, identify risk factors of OPVF, and determine the impact on overall survival (OS). METHODS: We performed a longitudinal single-center retrospective cohort study involving patients with histologically proven NSCLC of any stage. Chest-abdomen-pelvis computed tomography (CAP CT) at diagnosis and during follow-up were double-blind reviewed to determine OPVF site, count, type, time to incident OPVF, and trabecular volumetric bone density (TVBD). An institutional expert committee adjudicated discrepancies. Binary logistic regression was used to predict the occurrence of incident OPVF. OS was calculated using the Kaplan-Meier method. RESULTS: We included 289 patients with a median follow-up of 29.7 months. OPVF prevalence was 10.7% at inclusion and 23.2% at the end of follow-up. Cumulative incidence was 12.5%, with an incidence rate of 4 per 100 patient-years. Median time to incident OPVF was 13 months (IQR: 6.7-21.2). Seven of the 36 patients with incident OPVF received denosumab or bisphosphonates. In multivariable analysis, independent risk factors for incident OPVF were BMI < 19 kg/m2 (OR: 5.62, 95%CI 1.84-17.20, p = 0.002), lower TVBD (OR: 0.982 per HU, 95%CI 0.97-0.99, p = 0.001) and corticosteroid use (OR: 4.77, 95%CI: 1.76-12.89, p = 0.001). OPVF was not significantly associated with OS. CONCLUSIONS: Osteoporosis should be screened for in NSCLC patients. Thoracic oncologists must broaden the use of steroid-induced osteoporosis recommendations.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ebstein E, Brocard P, Soussi G, et al. Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study. Eur J Cancer. 2024. PMID: 38340385. doi:10.1016/j.ejca.2024.113604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。